Evaluating EWPPT and NECT for People With Schizophrenia
NCT07932236, Not applicable, Enrolling by invitation, City University of Hong Kong
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Evaluating EWPPT and NECT for People With Schizophrenia | ClinicalTrials.gov |
| NCT number | NCT07932236 | ClinicalTrials.gov |
| Status | Enrolling by invitation | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 210 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | City University of Hong Kong | ClinicalTrials.gov |
| Conditions | Schizophrenia Patients | ClinicalTrials.gov |
| Interventions | Enhanced WELLFOCUS PPT, Culturally adapted NECT | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change of Personal Recovery from T1 to T3 | Pre-intervention (Baseline/T1), immediately post-Intervention (T2), and 3-month follow-up (T3) | The subjective recovery process of patients is quantified via The Chinese version of the Recovery Assessment Scale (Corrigan et al., 1999; Mak et al., 2016). Comprising 24 items scored on a 5-point Likert scale from 1 (strongly disagree) to 5 (strongly agree), it measures dimensions of hope and self-determination. A sample item is "I have my own plan for how to stay or become well." | ClinicalTrials.gov |
| Primary | Change of Quality of Life from T1 to T3 | Pre-intervention (Baseline/T1), immediately post-Intervention (T2), and 3-month follow-up (T3) | Subjective quality of life is evaluated using a translated subscale extracted from the Manchester Short Assessment of Quality of Life (MANAS; Priebe et al., 1999). This instrument contains 12 items in total, structured around a 7-point Likert satisfaction scale ranging from 1 (strongly disagree) to 7 (strongly agree). A sample item is "In general I am satisfied with my life as a whole." It concludes with binary (Yes/No) objective questions regarding recent social support. | ClinicalTrials.gov |
| Primary | Change of Wellbeing from T1 to T3 | Pre-intervention (Baseline/T1), immediately post-Intervention (T2), and 3-month follow-up (T3) | Subjective psychological well-being is tracked using The Short Chinese Warwick-Edinburgh Mental Well-being Scale (Ng et al., 2014; Stewart-Brown et al., 2009). This brief 7-item scale captures individual's wellbeing on a 5-point Likert scale ranging from 1 (none of the time) to 5 (all the time). A sample item is "Dealing with problems well." | ClinicalTrials.gov |
| Secondary | Change of Self-Efficacy from T1 to T3 | Pre-intervention (Baseline/T1), immediately post-Intervention (T2), and 3-month follow-up (T3) | Perceived competence in dealing with stressful situations is evaluated using The Chinese General Self-Efficacy Scale (Schwarzer \& Jerusalem, 1995). This 10-item instrument utilizes a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree). A sample item is "When I am confronted with a problem, I can usually find several solutions." | ClinicalTrials.gov |
| Secondary | Change of Meaning in Life from T1 to T3 | Pre-intervention (Baseline/T1), immediately post-Intervention (T2), and 3-month follow-up (T3) | The capacity to construct personal meaning across life domains is captured using The Perceived Personal Meaning Scale (PPMS; Wong, 1998). This 8-item tool measures seven domains (achievement, relationship, religion, self-transcendence, self-acceptance, intimacy, and fair treatment) on a 9-point Likert scale ranging from 1 (strongly disagree) to 9 (strongly agree). A sample item is "My life as a whole has meaning." | ClinicalTrials.gov |
| Other | Change of Strength Use from T1 to T3 | Pre-intervention (Baseline/T1), immediately post-Intervention (T2), and 3-month follow-up (T3) | The extent to which people use their strength is evaluated using The Chinese version of the Strengths Use Scale (Govindji and Linley, 2007). This 14-item measure utilizes a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree). A sample item is "I am able to use my strengths in different ways." This outcome is administered exclusively to Trial Arm 1 (Enhanced WELLFOCUS PPT) as an internal mechanism indicator. | ClinicalTrials.gov |
| Other | Change of Self-Stigma from T1 to T3 | Pre-intervention (Baseline/T1), immediately post-Intervention (T2), and 3-month follow-up (T3) | The level of internalized negative stereotypes is quantified via The Self-Stigma Scale (SSS; Mak \& Cheung, 2010). This 9-item measure utilizes a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree), assessing how deeply individuals embed stigma into their recovery identity. A sample item states "I avoid interacting with others because I am a person in recovery of mental illness." This outcome is administered exclusively to Trial Arm 2 (Culturally Adapted NECT) as an internal mechanism indicator. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)